drugset / Trial / NCT03512873

A Clinical Study of Tranilast in the Treatment of Scleredema Diabeticorum

NCT03512873

NaSingle-groupOpen-labelTreatment

Summary

56 patients with scleredema diabeticorum will be selected to receive treatment of tranilast. After a period of time ,we can determine the efficacy of the drug by detecting the the thickness of skin before and after treatment.

Timeline

Start
2018-06
Primary completion
2020-06
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranilast Small molecule 0.1 g

Indications